Investors

Corporate Profile
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
Stock Information
AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.90
Change (%) Stock is Up 0.03 (0.51%)
Volume20,733
Data as of 08/26/16 3:59 p.m. ET
Stock chart for: AGLE.O.  Currently trading at $5.90 with a 52 week high of $12.75 and a 52 week low of $3.89.

Recent NewsMore >>
08/09/16

Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results

AUSTIN, Texas, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer, today r

Read More

07/18/16

Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer

--EMA Issued a Positive Opinion for Orphan Drug Designation for AEB1102-- --Initiated Two Phase 1 Clinical Trials of AEB1102 for Treatment of Hyperargininaemia and Hematological Malignancies-- AUSTIN, Texas, July 18, 2016 (GLOBE NEWSWIRE) -- Ae

Read More

05/23/16

Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency

AUSTIN, Texas, May 23, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and can

Read More

Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.